TrialPath

Find a study

Browse recruiting studies near you — free to check, always your choice.

Match me to a study

83 studies

Recruiting now, in plain language. Every study is watched over by an independent ethics board.

  • DepressionAnxiety

    Acceptance and Commitment Therapy for Adolescents and Young Adults With Sickle Cell Disease

    Testing whether therapy sessions can help teens and young adults with sickle cell cope with

    📍 Children's Hospital Los Angeles · Los Angeles, CA · Get directions →

    The current study seeks to build on previous research that demonstrates the efficacy of Acceptance and Commitment Therapy in combating stigma by investigating the feasibility and acceptability of a protocol to support Black adolescents and young adults in coping with race related stress. The study will consist of a small, purposeful, non-randomized sample (N = 30) of clients enrolled into a 10-session Acceptance and Commitment Therapy group.

    ✓ Study care freePhase 1Ages 14–21Learn more →
  • Sickle cell disease

    A Phase 1b, Open-Label Study of DISC-3405 in Participants With Sickle Cell Disease (SCD)

    Testing different doses of DISC-3405 to check safety in sickle cell disease

    📍 University of Alabama at Birmingham · Birmingham, AL · +6 more US sites · Get directions →

    This is an open-label, multicenter, within-participant dose-escalation study examining up to 3 dose levels of DISC-3405 and will assess the safety, tolerability, PK, and PD of DISC 3405 in participants with sickle cell disease.

    ✓ Study care freePhase 1Ages 18+Learn more →
  • Fatty liver disease (NASH/MASH)

    📍 Arizona Liver Health · Chandler, AZ · +1 more US site · Get directions →

    This study is researching an experimental drug called ALN-CIDEB, also referred to as "study drug". The study is focused on participants with metabolic dysfunction-associated steatotic liver disease (MASLD) (Part A) and metabolic dysfunction-associated steatohepatitis (MASH) (Part B).

    ✓ Study care freePhase 1Ages 18–65Learn more →
  • Fatty liver disease (NASH/MASH)

    A Research Study of a Potential New Medicine (NNC4005-0001) for Liver Disease in Adult Participants With Increased Body Weight and Liver Fat

    Testing a new medicine for liver disease in adults with extra body fat

    📍 Altasciences Clinical Company, Inc · Montreal, Quebec · Get directions →

    The purpose of this clinical study is to find out if NNC4005-0001 is well-tolerated and safe for people who have increased body weight and increased liver fat. Participants will receive either NNC4005-0001, which is the treatment being tested, or a placebo, which is a treatment that contains no active medicine.

    ✓ Study care freePhase 1Ages 18–69Learn more →
  • Fatty liver disease (NASH/MASH)

    A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH

    Testing how efimosfermin alfa compares with placebo for MASH with scarred liver tissue

    💵 May compensate

    📍 GSK Investigational Site · Arcadia, CA · +39 more US sites · Get directions →

    The purpose of this study is to assess the safety and efficacy of efimosfermin alfa in the resolution of steatohepatitis and improvement of liver-related clinical outcome compared to placebo in individuals with MASH and biopsy-confirmed F2- or F3-stage fibrosis.

    ✓ Study care freePhase 3Ages 18–75Learn more →
  • Anxiety

    Study to Evaluate the Efficacy and Safety of VQW-765 for the On-Demand Treatment of Social Anxiety Disorder

    Testing a single oral dose medicine versus placebo for social anxiety in adults

    📍 Vanda Investigational Site · Phoenix, AZ · +30 more US sites · Get directions →

    This is a multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of a single oral dose of VQW-765 compared to placebo in adults with social anxiety disorder.

    ✓ Study care freePhase 3Ages 18–65Learn more →
  • DepressionAnxiety

    ACT for Individuals With MNCD and Their Care Partners

    Testing acceptance commitment therapy for depression and anxiety in dementia

    📍 Texas Tech University Plaza Building · Lubbock, TX · Get directions →

    This project aims to implement and evaluate a dyadic intervention (i.e., acceptance commitment therapy) for persons with AD/ADRD and their care partners. We hypothesize the intervention will be feasible, acceptable, and show preliminary efficacy of the dyadic interveniotns.

    ✓ Study care freePhase 1Ages 18+Learn more →
  • Heart / cardiovascular diseaseKidney disease

    A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)

    Testing whether orforglipron changes heart outcomes in adults with heart disease and/or kidney

    📍 Instituto de Investigaciones Clínicas Bahia Blanca · Bahía Blanca, · Get directions →

    The purpose of this study is to measure cardiovascular outcomes with orforglipron compared with placebo in participants with atherosclerotic cardiovascular disease (ASCVD) and/or chronic kidney disease (CKD). Participation in the study will last about 5 years.

    ✓ Study care freePhase 3Ages 50+Learn more →
  • Type 2 diabetesFatty liver disease (NASH/MASH)

    A Phase 1b Study of QX1206 in T2DM Patients With NAFLD

    Testing QX1206 in people with type 2 diabetes and fatty liver

    📍 Centricity Research Toronto LMC. · Toronto, · Get directions →

    This is an open label phase 1b trial of QX1206 in patients with T2DM and with NAFLD. Laboratory tests and other measurements will be assessed prior to the first dose of study treatment and throughout the study to determine the recommended phase 2 dose.

    ✓ Study care freePhase 1Ages 18–64Learn more →
  • Sickle cell disease

    Escalating Doses of VAS-101 in Subjects With Stable Sickle Cell Disease

    Testing higher doses of VAS-101 in people with stable sickle cell disease

    💵 May compensate

    📍 National Institutes of Health Clinical Center · Bethesda, MD · Get directions →

    Background: Sickle cell disease (SCD) is an inherited blood disorder. The disease affects the ability of red blood cells to carry oxygen.

    ✓ Study care freePhase 1Ages 18–90Learn more →
  • Sickle cell disease

    A Safety, Efficacy, and Pharmacokinetic (PK) Study of HBI-002, an Oral Carbon Monoxide (CO) Therapeutic, in Subjects With Sickle Cell Disease (SCD)

    Testing the safety and how an oral carbon monoxide liquid works in sickle cell disease

    📍 Cevaxin - The Panama Clinic · Panama City, · Get directions →

    This is a multi-center, open label Phase 2a clinical trial in subjects with sickle cell disease to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of HBI-002, an orally administered liquid containing carbon monoxide (CO), with doses daily for 14 days.

    ✓ Study care freePhase 1Ages 18–55Learn more →
  • DepressionAnxiety

    Perinatal Depression & Anxiety (PDA) and Maternal Gut Microbiome

    Studying how gut bacteria in pregnant people relates to depression and anxiety

    📍 Sunnybrook Health Science Center · Toronto, Ontario · Get directions →

    Perinatal depression and anxiety (PDA) are the leading causes of maternal mortality in developed countries. Women with a history of depression have a 20 fold higher risk of PDA at subsequent pregnancies.

    ✓ Study care freePhase 2Ages 18–43WomenLearn more →
  • DepressionAnxiety

    Nebulized Ketamine for the Treatment of Major Depressive Disorder

    Testing a breathing mist of ketamine to reduce symptoms of major depression

    📍 Maimonides Medical Center · Brooklyn, NY · Get directions →

    This is a double-blind active placebo controlled clinical trial for individuals with moderate to severe depression. The purpose of this study is to assess if nebulized ketamine can reduce depressive symptoms.

    ✓ Study care freePhase 3Ages 18–88Learn more →
  • Sickle cell disease

    The Efficacy and Safety of Rilzabrutinib in Participants Aged 10 to 65 Years With Sickle-cell Disease

    Testing rilzabrutinib for safety and effectiveness in sickle-cell disease

    📍 University of Alabama at Birmingham- Site Number : 8400003 · Birmingham, AL · +15 more US sites · Get directions →

    This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group, flexible-adaptive, group-sequential study (Part A), followed by an open-label LTE period (Part B) to investigate the efficacy, and safety of rilzabrutinib in participants with sickle-cell disease (SCD). Study details include: * Study duration: a 52-week double-blind period (Part A), followed by an open-label LTE period (Part B).

    ✓ Study care freePhase 3Ages 10–65Learn more →
  • Sickle cell disease

    Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease

    Testing whether extra arginine lowers pain in children with sickle cell

    📍 Children's Healthcare fo Atlanta at Hughes Spalding · Atlanta, GA · +1 more US site · Get directions →

    The purpose of this study is to determine whether giving extra arginine to patients with sickle cell disease seeking treatment for vaso-occlusive painful events (VOE) will decrease pain scores, decrease need for pain medications or decrease length of hospital stay or emergency department visit.

    ✓ Study care freePhase 1Ages 7–21Learn more →
  • DepressionAnxiety

    Creatine for Depressed Male and Female Methamphetamine Users

    Testing whether creatine helps depression and anxiety in people who use meth

    📍 Montana State University College of Nursing (Missoula campus) · Missoula, MT · Get directions →

    * Assess the antidepressant/anxiolytic effect of creatine in male and female methamphetamine users * Assess creatine's effect on methamphetamine use * Assess the safety of creatine in male methamphetamine users with depression

    ✓ Study care freePhase 3Ages 18–59Learn more →
  • Fatty liver disease (NASH/MASH)

    A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis

    Testing a drug to treat fat buildup liver disease in people with stage 2 or 3 fibrosis

    📍 Akero Clinical Study Site · Birmingham, AL · +39 more US sites · Get directions →

    This is a multi-center evaluation of efruxifermin (EFX) in a randomized, double-blind, placebo-controlled study in subjects with non-cirrhotic NASH/MASH and fibrosis stage 2 or 3 (F2 or F3). The study will enroll subjects in two cohorts for a total samples size of 1650 subjects.

    ✓ Study care freePhase 3Ages 18–80Learn more →
  • Fatty liver disease (NASH/MASH)

    A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)

    Testing whether two doses of pegozafermin are safe and work for liver scarring in adults with MASH

    📍 89bio Clinical Study Site · Birmingham, AL · +39 more US sites · Get directions →

    The study will assess the efficacy and safety of 2 dose regimens of pegozafermin compared to placebo for the treatment of liver fibrosis stage F2 or F3 in adult participants with MASH.

    ✓ Study care freePhase 3Ages 18–80Learn more →
  • Obesity / overweightFatty liver disease (NASH/MASH)

    Human Models of Selective Insulin Resistance: Alpelisib, Part I

    Testing how insulin works in healthy people versus people at risk for type 2 diabetes

    💵 May compensate

    📍 Columbia University Irving Medical Center · New York, NY · Get directions →

    The goal of this clinical trial is to understand how the blood sugar-lowering hormone insulin works in healthy adults versus those who are at risk for type 2 diabetes. The study will use a drug called alpelisib, which interferes with insulin's actions in the body, to answer the study's main question: does the liver continue to respond to insulin's stimulation of fat production even when it loses the ability to stop making glucose (sugar) in response to insulin.

    ✓ Study care freePhase 1Ages 18–70Learn more →
  • Sickle cell disease

    RH Genotype Matched RBC Transfusions

    Testing whether matching donor red blood cells by RH type helps people with sickle cell who need

    📍 Children's Hospital of Philadelphia · Philadelphia, PA · Get directions →

    To determine the feasibility and efficacy of matching donor red cells by RH genotype for a cohort of chronically transfused patients with SCD.

    ✓ Study care freePhase 1Ages 1+Learn more →
  • Heart / cardiovascular diseaseHigh blood pressure

    EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease

    Testing a drug taken with empagliflozin in adults with type 2 diabetes and heart disease

    📍 Pinnacle Research Group, LLC · Anniston, AL · +39 more US sites · Get directions →

    This study is open to adults with type 2 diabetes, high blood pressure, and cardiovascular disease. People can join the study if they have these conditions and do not have a history of heart failure.

    ✓ Study care freePhase 3Ages 18+Learn more →
  • Anxiety

    📍 Servicios Especializados En Ensayos Clinicos, Seec, Sc · Mexico City, Mexico City · Get directions →

    To evaluate the superiority of cognitive behavioral therapy using the Aurora® digital medical device + conventional drug treatment, compared to conventional drug treatment alone, in reducing anxiety symptoms, as assessed by the change in the GAD-7 scale at 12 weeks of treatment, relative to baseline.

    ✓ Study care freePhase 3Ages 18–65Learn more →
  • Fatty liver disease (NASH/MASH)

    A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH

    Testing whether pegozafermin is safe and works for MASH-related liver cirrhosis

    💵 May compensate

    📍 89bio Clinical Study Site · Birmingham, AL · +39 more US sites · Get directions →

    The study will assess the efficacy and safety of pegozafermin administered in participants with compensated cirrhosis due to MASH (biopsy-confirmed fibrosis stage F4 MASH \[previously known as nonalcoholic steatohepatitis, NASH\]).

    ✓ Study care freePhase 3Ages 18–75Learn more →
  • Sickle cell disease

    Transplantation of Clustered Regularly Interspaced Short Palindromic Repeats Modified Hematopoietic Progenitor Stem Cells (CRISPR_SCD001) in Patients With Severe Sickle Cell Disease

    Testing a one-time blood stem cell transplant using gene editing for severe sickle cell disease

    📍 University of California, Los Angeles · Los Angeles, CA · +1 more US site · Get directions →

    This is an open label, non-randomized, 2-center, phase 1/2 trial of a single infusion of sickle allele modified cluster of differentiation (CD34+) hematopoietic stem progenitor cells (HSPCs) in subjects with in subjects ≥12 years old to 35 years old severe Sickle Cell Disease (SCD). The study will evaluate the hematopoietic stem cell transplantation (HSCT) using CRISPR/Cas9 edited red blood cells (known as CRISPR\_SCD001 Drug Product).

    ✓ Study care freePhase 1Ages 12–35Learn more →
  • Heart / cardiovascular diseaseKidney disease

    Sotagliflozin to Slow Kidney Function Decline in Persons With Type 1 Diabetes and Diabetic Kidney Disease

    Testing whether sotagliflozin can slow kidney damage in type 1 diabetes

    💵 May compensate

    📍 Stanford University Medical Center · Stanford, CA · +12 more US sites · Get directions →

    Powerful new drugs that can prevent or delay end stage kidney disease (ESKD) - so called sodium-glucose cotransporter-2 inhibitors (SGLT2i) - are now available for patients with type 2 diabetes. Whether these drugs have similar effects in patients with type 1 diabetes (T1D) remains unknown because of the few studies in this population, due to concerns about the increase in risk of diabetic ketoacidosis (DKA, a serious, potentially fatal acute complication of diabetes due to the accumulation of substances called ketone bodies) observed with SGLT2i therapy in T1D.

    ✓ Study care freePhase 3Ages 18–75Learn more →
  • DepressionAnxiety

    Open-Label Psilocybin Study in Transdiagnostic Population

    Testing psilocybin for safety and symptom changes in people with depression or anxiety

    📍 Connecticut Mental Health Center - Yale School of Medicine · New Haven, CT · Get directions →

    The primary objective of this study is to investigate the safety, feasibility, and tolerability of psilocybin treatment in individuals with functional impairment due to psychiatric symptoms. The secondary objective of this study is to determine whether individuals with functional impairments due to psychiatric symptoms will experience statistically significant symptom reduction and functional improvement from baseline symptom measurements (Visit 3) to 1-week (Visit 7), 4-weeks (Visit 8), and 6-weeks (Visit 9) post dosing.

    ✓ Study care freePhase 1Ages 18+Learn more →
  • DepressionAnxiety

    Use of a Generative AI (Gen-AI) Chatbot for Anxiety and Depression Among Persons With Cannabis Use

    Testing a chatbot to support people using cannabis with anxiety or depression

    📍 46 Centerra Parkway, Suite 300, Office #333S · Lebanon, NH · Get directions →

    This study tests a chatbot called Therabot-CALM to help people who use cannabis with anxiety and/or low mood. Participants will do questionnaires, try the chatbot for 4 weeks, and join virtual interviews to give feedback on how usable and helpful it feels. The goal is to see if the chatbot is acceptable to users and can improve symptoms.

    ✓ Study care freePhase 1Ages 18+Learn more →
  • Anxiety

    The Impact of Focused Ultrasound Thalamotomy of the Anterior Nucleus for Focal-Onset Epilepsy on Anxiety

    Testing whether focused ultrasound thalamotomy can improve anxiety

    📍 The Ohio State University · Columbus, OH · Get directions →

    The purpose of this study is to evaluate the feasibility, safety, and effects on anxiety of high intensity focused ultrasound ablation (FUSA) in patients suffering from treatment-refractory focal epilepsy and anxiety. FUSA is a non-invasive neurosurgical procedure that uses ultrasound waves, sent directly through the scalp and skull, to precisely target small abnormal areas of the brain.

    ✓ Study care freePhase 1Ages 18–65Learn more →
  • Sickle cell disease

    Cannabidiol in Sickle Cell Disease

    Testing twice-daily cannabidiol doses for people with sickle cell disease

    📍 Icahn School of Medicine at Mount Sinai · Manhattan, NY · Get directions →

    Randomized, placebo-controlled, double masked, dose finding study of twice daily cannabidiol given at 3 dose levels, 200mg, 400mg, and 600mg, compared to placebo for 4 weeks.

    ✓ Study care freePhase 1Ages 18+Learn more →
  • Sickle cell disease

    Gene Editing For Sickle Cell Disease

    Testing whether gene editing is safe for people with sickle cell disease

    📍 St. Jude Children's Research Hospital · Memphis, TN · Get directions →

    This study is being done to test the safety of a new treatment called gene editing in Sickle Cell Disease (SCD) patients and to see if a single dose of this genetically modified cellular product will increase the amount of a certain hemoglobin called fetal hemoglobin (HbF) and help reduce the symptoms of SCD. Primary Objective * To assess the safety of autologous infusion of clustered regularly interspaced palindromic repeats (CRISPR)/ CRISPR associated protein (Cas9)-edited CD34+ hematopoietic stem and progenitor cells (HSPCs) in patients with severe SCD.

    ✓ Study care freePhase 1Ages 18–24Learn more →
  • Sickle cell disease

    Study of a Single Dose of a 21-valent Pneumococcal Conjugate Vaccine in Children and Adolescents With Sickle Cell Disease

    Testing a single pneumococcal vaccine dose in children with sickle cell disease

    📍 Site # 8400006 · Atlanta, GA · +4 more US sites · Get directions →

    The purpose of this study is to measure whether PCV21 vaccine (investigational pneumococcal vaccine) is safe and can help the body to develop germ-fighting agents called "antibodies" (immunogenicity) compared with 20vPCV (licensed pneumococcal vaccine) when given as a single dose to children aged 2 to 17 years with sickle cell disease who had received or not a previous vaccination with pneumococcal conjugate or pneumococcal polysaccharide vaccine.

    ✓ Study care freePhase 3Ages 2–17Learn more →
  • DepressionAnxiety

    Enhancing Transdiagnostic Mechanisms of Cognitive Dyscontrol (R33)

    Testing a cognitive training program to see brain and thinking changes in people with depression or

    📍 UC San Diego · San Diego, CA · Get directions →

    The proposed project aims to test the cognitive and neural effects of a cognitive training in a sample of individuals seeking treatment for anxiety, depression, or traumatic stress symptoms. Participants will be randomly assigned to one of two groups.

    ✓ Study care freePhase 2Ages 21–55Learn more →
  • Obesity / overweightHeart / cardiovascular disease

    Prevention of Progression of Prediabetes, Obesity and CV Risk

    Testing ways to stop prediabetes and obesity from getting worse

    💵 May compensate

    📍 University of Texas Health Science Center at San Antonio · San Antonio, TX · Get directions →

    The investigators are studying how to help people with prediabetes (Pre-DM) and obesity. The goal is to use new and affordable treatments to bring blood sugar levels back to normal and help participants to lose weight.

    ✓ Study care freePhase 1Ages 18+Learn more →
  • Fatty liver disease (NASH/MASH)

    Evaluating the Pharmacokinetics and Safety of Miricorilant

    Testing how a drug works in the body and its safety in adults with MASH

    💵 May compensate

    📍 Site# 433 · San Antonio, TX · Get directions →

    A Phase 1b, Open-Label Study Evaluating the Pharmacokinetics and Safety of Miricorilant in Adult Patients With Presumed Metabolic Dysfunction-Associated Steatohepatitis (MASH)

    ✓ Study care freePhase 1Ages 18–75Learn more →
  • Fatty liver disease (NASH/MASH)

    Bicalutamide Therapy in Young Women With NAFLD and PCOS

    Testing bicalutamide in young women with fatty liver inflammation (NASH) and PCOS

    📍 University of California San Francisco · San Francisco, CA · Get directions →

    Nonalcoholic steatohepatitis (NASH), or fat-related liver inflammation and scarring is projected to be the leading cause of cirrhosis in the United States (U.S.) within the next few years. Women are at disproportionate risk for NASH, with approximately 15 million U.S.

    ✓ Study care freePhase 1Ages 18–42WomenLearn more →
  • Obesity / overweightHeart / cardiovascular disease

    Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity

    Testing whether maridebart cafraglutide lowers heart risks in people with heart disease and obesity

    📍 Alliance For Multispecialty Research - Daphne · Daphne, AL · +39 more US sites · Get directions →

    The primary objective of this trial is to demonstrate that maridebart cafraglutide is superior to placebo when given as an adjunct to standard of care with respect to reducing cardiovascular (CV) morbidity and mortality.

    ✓ Study care freePhase 3Ages 45–99Learn more →
  • Obesity / overweightHeart / cardiovascular disease

    Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity

    Testing maridebart cafraglutide with standard care to reduce heart failure events in obese people

    💵 May compensate

    📍 University of Alabama Saint Vincent's Birmingham · Birmingham, AL · +39 more US sites · Get directions →

    This trial will examine if maridebart cafraglutide as an adjunct to standard of care will lead to a reduction in heart failure (HF) events such as HF hospitalizations and urgent HF visits, cardiovascular (CV) deaths and improvement in HF symptoms in participants with HF with preserved ejection fraction (HFpEF) and HF with mildly reduced ejection fraction (HFmrEF) who are obese. This is a phase 3, global, multicenter, 2-part trial with a double-blind period and an open-label extension (OLE).

    ✓ Study care freePhase 3Ages 18–99Learn more →
  • Obesity / overweightHeart / cardiovascular disease

    A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity

    Testing how well NNC0487-0111 works versus placebo in heart failure with excess body weight

    📍 Advanced Cardiovascular, LLC · Alexander City, AL · +39 more US sites · Get directions →

    This study is being done to look at the safety and effect of NNC0487-0111 in people with Heart Failure with preserved Ejection Fraction (HFpEF) or Heart Failure with mildly reduced Ejection Fraction (HFmrEF) and excess body weight when compared to placebo. The purpose of this clinical study is to find out if NNC0487-0111 is safe and effective for treating people who have HFpEF or HFmrEF and excess body weight.

    ✓ Study care freePhase 3Ages 18+Learn more →
  • Sickle cell disease

    A Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia

    Testing long-term treatment with a new medicine for sickle cell or thalassaemia

    📍 Univ of Alabama Birmingham · Birmingham, AL · +38 more US sites · Get directions →

    Etavopivat is a new medicine under development for treating blood disorders like sickle cell disease and thalassaemia. Sickle cell disease and thalassaemia are inherited blood disorders that affect haemoglobin.

    ✓ Study care freePhase 3Ages 2+Learn more →
  • Sickle cell disease

    A Study to Evaluate BMS-986470 in Healthy Volunteers and Participants With Sickle Cell Disease

    Testing how BMS-986470 affects the body and safety in sickle cell disease

    📍 University of Alabama at Birmingham · Birmingham, AL · +18 more US sites · Get directions →

    The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics and pharmacodynamics, pH and food effect, and preliminary efficacy of BMS-986470 in healthy volunteers and participants with sickle cell disease.

    ✓ Study care freePhase 1Ages 18+Learn more →
  • Sickle cell disease

    Partial Stem Cell Transplant for Sickle Cell Disease From Matched Donors

    Testing a partial stem cell transplant from matched donors for severe sickle cell disease or

    📍 National Institutes of Health Clinical Center · Bethesda, MD · Get directions →

    This is a non-ablative (partial) stem cell transplant for patients with severe sickle cell disease or beta-thalassemia requiring red cell transfusions. The intensity of the transplant is slightly increased from our previous transplant regimens.

    ✓ Study care freePhase 1Ages 4–65Learn more →
  • Sickle cell disease

    Study to Evaluate the Safety and Tolerability of Escalating Doses of Fostamatinib in Subjects With Stable Sickle Cell Disease

    Testing how safe escalating doses of fostamatinib are in people with stable sickle cell disease

    📍 National Institutes of Health Clinical Center · Bethesda, MD · Get directions →

    Background: Sickle cell disease (SCD) is a genetic disease that causes the body to produce abnormal ( sickled ) red blood cells. SCD can cause anemia and life-threatening complications in the lungs, heart, kidney, and nerves.

    ✓ Study care freePhase 1Ages 18–65Learn more →
  • Sickle cell disease

    Hematopoietic Stem Cell BCL11A Enhancer Gene Editing for Severe β-Hemoglobinopathies

    Testing gene editing in stem cells for severe sickle cell disease

    📍 Boston Children's Hospital · Boston, MA · Get directions →

    A promising approach for the treatment of genetic diseases is called gene therapy. Gene therapy is a relatively new field of medicine that uses genetic material (mostly DNA) from the patient to treat his or her own disease.

    ✓ Study care freePhase 1Ages 13–40Learn more →
  • Anxiety

    Cannabidiol-Assisted Learning for Managing Generalized Anxiety Disorder

    Testing cannabidiol added to talk therapy for adults with generalized anxiety

    📍 Wayne State University School of Medicine, Tolan Park Medical Building · Detroit, MI · Get directions →

    This randomized, double-blind, placebo-controlled clinical trial investigates the use of Food and Drug Administration (FDA)-approved cannabidiol (EPIDIOLEX®) as an adjunct to cognitive behavioral therapy (CBT) in adults with generalized anxiety disorder (GAD). The study aims to evaluate whether cannabidiol-assisted CBT enhances emotion regulation via dorsomedial prefrontal cortex (dmPFC) activation and improves anxiety symptom outcomes compared to CBT with placebo.

    ✓ Study care freePhase 3Ages 18–45Learn more →
  • Heart / cardiovascular disease

    COLchicine and Non-enteric Coated Aspirin in the Cardiovascular Outcomes Trial of Patients With Type 2 Diabetes

    Testing colchicine and plain aspirin, alone or together, for heart outcomes in high-risk type 2

    📍 Curtin University · Bentley, Western Australia · Get directions →

    To evaluate the efficacy and safety of colchicine and non-enteric coated aspirin, combined or alone, to improve cardiovascular outcomes in high-risk patients with type 2 diabetes.

    ✓ Study care freePhase 3Ages 55–80Learn more →
  • Sickle cell disease

    SCD Stem Cell Mobilization and Apheresis Using Motixafortide

    Testing whether motixafortide is safe and can raise stem cells in people with sickle cell disease

    📍 University of Alabama at Birmingham · Birmingham, AL · +2 more US sites · Get directions →

    This study is being done to see if the study drug, motixafortide, is safe in participants with sickle cell disease (SCD). Investigators also want to see if the drug will help the body increase the number of stem cells that can be collected for possible future transplant use.

    ✓ Study care freePhase 1Ages 18+Learn more →
  • Sickle cell disease

    📍 University Of Alabama · Birmingham, AL · +13 more US sites · Get directions →

    A phase III, multi-center, randomized, placebo-controlled, double-blind study to assess efficacy and safety of crizanlizumab (5 mg/kg) versus placebo, with or without hydroxyurea/hydroxycarbamide therapy, in adolescent and adult Sickle Cell Disease patients with frequent vaso-occlusive crises.

    ✓ Study care freePhase 3Ages 12–100Learn more →
  • Type 2 diabetesHeart / cardiovascular disease

    FES Cycling With BFR in the Spinal Cord Injury Population

    Testing a cycling exercise program with added arm-leg pressure for people with spinal cord injury

    📍 Lyndhurst Centre · Toronto, Ontario · Get directions →

    Cardiometabolic Disease (CMD) is the silent killer within the spinal cord injury/disease (SCI/D) population. Many SCI/D patients' initial CMD presentation is with a heart attack, stroke, or sudden cardiac death, highlighting the need for interventions to reduce CMD risk.

    ✓ Study care freePhase 1Ages 18–75Learn more →
  • Fatty liver disease (NASH/MASH)

    A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH

    Testing a medicine called efruxifermin in people with compensated liver scarring from NASH/MASH

    💵 May compensate

    📍 Akero Clinical Study Site · Birmingham, AL · +39 more US sites · Get directions →

    This is a multi-center evaluation of efruxifermin (EFX) in a randomized, double-blind, placebo-controlled study in subjects with compensated cirrhosis due to NASH/MASH.

    ✓ Study care freePhase 3Ages 18–80Learn more →
  • Sickle cell disease

    Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease

    Testing the safety and effects of panobinostat in adults with sickle cell disease

    📍 Augusta University · Augusta, GA · Get directions →

    The goal of this clinical research study is to find out about the safety and effects of a drug called panobinostat when given to adults with sickle cell disease. Panobinostat is a pan histone deacetylase (HDAC) inhibitor.

    ✓ Study care freePhase 1Ages 18+Learn more →
  • Obesity / overweightHeart / cardiovascular disease

    Mechanisms of Semaglutide Therapy in Heart Failure Patients

    Testing how semaglutide works in people with heart failure and obesity

    📍 Greenstone Biosciences · Palo Alto, CA · +1 more US site · Get directions →

    Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist, primarily used for treatment of type-2 diabetes mellitus. GLP-1 receptors are present on pancreatic islet β-cells, δ-cells and α-cells.

    ✓ Study care freePhase 1Ages 20–80Learn more →
  • Sickle cell disease

    A Phase I/II Study of ITU512 in Healthy Participants and Patients With Sickle Cell Disease

    Testing how a new medicine works in healthy people and sickle cell patients

    📍 University of Alabama Birmingham · Birmingham, AL · +5 more US sites · Get directions →

    The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary food effect of ITU512 as well as the fetal hemoglobin (HbF)-inducing capacity of ITU512. This will be the first evaluation of the potential therapeutic effect of ITU512 in healthy participants and patients with sickle cell disease (SCD).

    ✓ Study care freePhase 1Ages 12–55Learn more →
  • Sickle cell disease

    Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders

    Testing a bone marrow transplant with lower-intensity treatment for kids with sickle cell and

    📍 Yale School of Medicine · New Haven, CT · +3 more US sites · Get directions →

    This study is designed to estimate the efficacy and toxicity of familial HLA mismatched bone marrow transplants in patients with non-malignant disease who are less than 21 years of age and could benefit from the procedure.

    ✓ Study care freePhase 1Learn more →
  • Sickle cell disease

    A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease

    Testing how well etavopivat lowers painful sickle cell crises and organ damage

    📍 Uni of Alabama at Birmingham · Birmingham, AL · +39 more US sites · Get directions →

    This study is conducted to confirm whether etavopivat works well at reducing the number of Vaso-occlusive crisis VOCs (sickle cell pain crises) caused by obstructions in blood vessels in adults and adolescents living with sickle cell disease. The study will also evaluate how well etavopivat can reduce the damage to different organs, improve your exercise tolerance and reduce fatigue in people with sickle cell disease.The participants will either get etavopivat or placebo.

    ✓ Study care freePhase 3Ages 12+Learn more →
  • Fatty liver disease (NASH/MASH)

    LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis

    Testing whether survodutide helps adults with MASH and moderate to advanced liver scarring

    💵 May compensate

    📍 University of Alabama at Birmingham · Birmingham, AL · +39 more US sites · Get directions →

    This study is open to adults who are at least 18 years old living with obesity and have: * a confirmed liver disease called non-alcoholic steatohepatitis (NASH)/metabolic associated steatohepatitis (MASH) and * moderate or advanced liver fibrosis People with a history of acute or chronic liver diseases other than MASH or chronic alcohol intake cannot take part in this study. The purpose of this study is to find out whether a medicine called survodutide helps people with MASH and moderate or advanced liver fibrosis improve their liver function.

    ✓ Study care freePhase 3Ages 18+Learn more →
  • DepressionAnxiety

    Affect of Duavive on Mood & Anxiety Symptoms

    Testing how Duavive affects mood and anxiety symptoms in early menopause women

    📍 St Joseph's Healthcare · Hamilton, Ontario · Get directions →

    This study evaluates the impact of conjugated estrogens/ bazedoxifene (CE/ BZA) on the mood (depression and anxiety) in peri- and early menopausal women.

    ✓ Study care freePhase 1Ages 45–60WomenLearn more →
  • Fatty liver disease (NASH/MASH)

    LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis

    Testing whether survodutide helps adults with NASH/MASH cirrhosis

    💵 May compensate

    📍 The Institute for Liver Health II DBA Arizona Clinical Trials · Peoria, AZ · +39 more US sites · Get directions →

    This study is open to adults who are at least 18 years old and have: * A confirmed liver disease called non-alcoholic steatohepatitis (NASH) or * A confirmed liver disease called metabolic-associated steatohepatitis (MASH) * BMI of 27 kg/m2 or more or * 25 kg/m2 or more if the participant is Asian. People with a history of other chronic liver diseases or high alcohol intake cannot take part in this study.

    ✓ Study care freePhase 3Ages 18+Learn more →
  • Fatty liver disease (NASH/MASH)

    A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH

    Testing the safety of an injected medicine in people with MASH and F2 or F3 scarring

    💵 May compensate

    📍 GSK Investigational Site · Arcadia, CA · +39 more US sites · Get directions →

    This study will evaluate the safety and tolerability of Efimosfermin Alfa for participants with known or suspected MASH with fibrosis consistent with stage F2 or F3.

    ✓ Study care freePhase 3Ages 18–75Learn more →
  • Sickle cell disease

    Methylphenidate to Address Attention and Executive Deficits Among Children With Sickle Cell Disease

    Testing whether children with sickle cell disease can take daily ADHD medicine and monitoring its

    📍 St. Jude Children's Research Hospital · Memphis, TN · Get directions →

    The purpose of this study is to determine if patients with sickle cell disease (SCD) can consistently take a drug called Methylphenidate (MPH) daily, once a day for 4 weeks to help with any thinking, attention or schoolwork problems and if they have any side effects. The study will assess any thinking or attention problems participants may have both before taking this drug and after.

    ✓ Study care freePhase 1Ages 8–17Learn more →
  • Heart / cardiovascular disease

    Canagliflozin Targeting Vascular Inflammation

    Testing canagliflozin to reduce blood vessel inflammation in cardiovascular disease

    💵 May compensate

    📍 University of Ottawa Heart Institute · Ottawa, Ontario · Get directions →

    CANTOR SING is a pilot single center double blinded randomized study. The investigators will compare the effect of canagliflozin (300 mg daily - intervention arm) vs.

    ✓ Study care freePhase 2Ages 18+Learn more →
  • Showing the first 60 of 83. Add filters or a location to narrow down.